Loading
Childhood cancers are rare, so no one country sees enough cases. Pool the treatment and outcome of every child treated anywhere into one governed dataset.
Paediatric oncology already treats most children on or according to cooperative-group protocols, with structured data. Linking cooperative-group databases (COG, SIOP Europe, and LMIC networks) into one federated real-world resource, including children treated off-protocol and in LMICs, would allow toxicity, late effects and rare subtype questions to be answered globally. The proposal funds the governance, common data model and federation.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Weak real-world evidence and registries, Rare and paediatric cancers without markets.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Weak real-world evidence and registries, Data silos.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Data silos, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.